ClinicalTrials.gg
CompletedNCT06821334Updated Feb 12, 2025

A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)

A Phase 1 interventional study of MK-6194 and Placebo in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 3 months ago, and no results have been posted to the registry.
  • Registered 9 months after the study started (first participant enrolled Apr 2024, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of this study is to learn how safe MK-6194 is in healthy Chinese adults and how well people tolerate it.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Is in good health
  • Has (BMI) within 18.0 to 28.0 kg/m\^2 (inclusive) and weight ≥50 kg

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • History of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Has a history of opportunistic infection, (HIV), , , tuberculosis
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Panel A

    Participants receive single dose subcutaneous (SC) injection of MK-6194 (Dose 1) or Placebo.

    Biological: MK-6194 · Biological: Placebo

  • Experimental
    Panel B

    Participants receive single dose subcutaneous (SC) injection of MK-6194 (Dose 2) or Placebo.

    Biological: MK-6194 · Biological: Placebo

  • Experimental
    Panel C

    Participants receive single dose subcutaneous (SC) injection of MK-6194 (Dose 3) or Placebo.

    Biological: MK-6194 · Biological: Placebo

Interventions

  • BiologicalMK-6194

    Subcutaneous Administration

  • BiologicalPlacebo

    Subcutaneous administration

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to 42 days post dose

  2. Number of Participants Who Discontinue Study Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to 42 days post dose

Secondary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Last Measurable Concentration (AUC0-Last) of MK-6194

    Blood samples will be collected at specified intervals to determine the AUC0-last of MK-6194.

    Time frame: Up to 42 days post dose

  2. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-6194

    Blood samples will be collected at specified intervals to determine the AUC0-inf of MK-6194.

    Time frame: Up to 42 days post dose

  3. Maximum Serum Concentration (Cmax) of MK-6194

    Blood samples will be collected at specified intervals to determine the Cmax of MK-6194.

    Time frame: Up to 42 days post dose

  4. Time to Maximum Serum Concentration (Tmax) of MK-6194

    Blood samples will be collected at specified intervals to determine the Tmax of MK-6194.

    Time frame: Up to 42 days post dose

  5. Apparent Terminal Half-life (t1/2) of MK-6194

    Blood samples will be collected at specified intervals to determine the t1/2 of MK-6194.

    Time frame: Up to 42 days post dose

  6. Apparent Clearance (CL/F) of MK-6194

    Blood samples will be collected at specified intervals to determine the CL/F of MK-6194.

    Time frame: Up to 42 days post dose

  7. Apparent Volume of Distribution during terminal phase (Vz/F) of MK-6194

    Blood samples will be collected at specified intervals to determine the Vz/F of MK-6194.

    Time frame: Up to 42 days post dose

  8. Incidence of Antidrug Antibodies (ADA) to MK-6194

    Blood samples will be collected at specified intervals to determine the ADA response to MK-6194.

    Time frame: Up to 42 days post dose

07

Study locations

1 site
  • Peking University Third Hospital (Site 0001)
    Beijing, Beijing 100191, China
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Aug 2024, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Feb 12, 2025
StartActual
Apr 23, 2024
Primary completionActual
Aug 9, 2024
CompletionActual
Aug 9, 2024
Last update
Feb 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06821334
Responsible party
Sponsor
First posted
Feb 12, 2025
Start date
Apr 23, 2024
Primary completion
Aug 9, 2024
Completion
Aug 9, 2024
Last update
Feb 12, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-6194

Start the discussion